Motor correlates of occipital glucose hypometabolism in parkinson's disease without dementia

Neurology

Volumn 52, Issue 3, 1999, Pages 541-546

  Bohnen, N I ^a   Minoshima, Satoshi ^a   Giordani, B ^b   Frey, K A ^a   Kuhl, D E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; OCCIPITAL LOBE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TASK PERFORMANCE; VISUAL CORTEX;

EID: 0033022353     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.3.541     Document Type: Article

References (30)

1. Van der Borght T, Minoshima S, Giordani B, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's disease matched for dementia severity. J Nucl Med 1997;38:797-802.
2. 18F]fluorodeoxyglucose method. Ann Neurol 1984;15:419-424.
3. Schwartzman RJ, Alexander GM, Ferraro TN, Grothusen JR, Stahl SM. Cerebral metabolism of parkinsonian primates 21 days after MPTP. Exp Neurol 1988;102:307-313.
4. Liu RS, Lin KN, Wang SJ, et al. Cognition and 99Tcm-HMPAO SPECT in Parkinson's disease. Nucl Med Commun 1992;13:744-748.
5. Peppard RF, Wayne Martin WR, Carr GD, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992;49:1262-1268.
6. Wang SJ, Liu RS, Liu HC, et al. Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization. Eur J Nucl Med 1993;20:339-344.
7. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust WJ. Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging 1994;15:329-335.
8. Bodis-Wollner I, Tagliati M. The visual system in Parkinson's disease. Adv Neurol 1993;60:390-394.
9. Bulens C, Meerwaldt JD, Van der Wildt GJ, Van Deursen JBP. Effect of levodopa treatment on contrast sensitivity in Parkinson's disease. Ann Neurol 1987;22:365-369.
10. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990;31:2473-2475.
11. Kori A, Miyashita N, Kato M, Hikosaka O, Usui S, Matsumura M. Eye movements in monkeys with local dopamine depletion in the caudate nucleus. II. Deficits in voluntary saccades. J Neurosci 1995;15:928-941.
12. Miyashita N, Hikosaka O, Kato M. Visual hemineglect induced by unilateral striatal dopamine deficiency in monkeys. Neuroreport 1995;6:1257-1260.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
14. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
15. Hutchins GD, Holden JE, Koeppe RA, Halama JR, Gatley SJ, Nickles RJ. Alternative approach to single-scan estimation of cerebral glucose metabolic rate using glucose analogs, with particular application to ischemia. J Cereb Blood Flow Metab 1984;4:35-40.
16. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme, 1988.
17. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:1528-1537.
18. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238-1248.
19. Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990;27:373-385.
20. Ebersbach G, Trottenberg T, Hättig H, Schelosky L, Schrag A, Poewe W. Directional bias of initial visual exploration: a symptom of neglect in Parkinson's disease. Brain 1996;119: 79-87.
21. Dominey PF, Arbib MA. A cortico-subcortical model for generation of spatially accurate sequential saccades. Cereb Cortex 1992;2:153-175.
22. Heilman KM, Watson RT, Valenstein E. Neglect and related disorders. In: Heilman KM, Valenstein E, eds. Clinical neuropsychology. 3rd ed. New York: Oxford University Press, 1993: 279-336.
23. Nobre AC, Sebestyen GN, Gitelman DR, Mesulam MM, Frackowiak RSJ, Frith CD. Functional localization of the system for visuospatial attention using positron emission tomography. Brain 1997;120:515-533.
24. Vandenberghe R, Dupont P, De Bruyn B, et al. The influence of stimulus location on the brain activation pattern in detection and orientation discrimination: a PET study of visual attention. Brain 1996;119:1263-1276.
25. Wenzel R, Bartenstein P, Dieterich M, et al. Deactivation of human visual cortex during involuntary ocular oscillations: a PET activation study. Brain 1996;119:101-110.
26. Paus C, Marrett S, Worsley KJ, Evans AC. Extraretinal modulation of cerebral blood flow in the human visual cortex: implication for saccadic suppression. J Neurophysiol 1995;74: 2179-2183.
27. Jellinger KA. Pathology of Parkinson's disease: changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991; 14:153-197.
28. Rougement D, Baron JC, Collard P, Bustany P, Comar D, Agid Y. Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1984;47:824-830.
29. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DE, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462-466.
30. Minoshima S, Foster NL, Frey KA, Wahl RL, Burdette JH, Kuhl DE. Can FDG PET distinguish dementia patients with cortical Lewy bodies from pure Alzheimer's disease? J Nucl Med 1997;38(suppl):70.